Last mentioned: Jul 8, 2026
Across the most recent 2 stories covering Seagen — 100% neutral sentiment, averaging 5/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived. See something wrong on this page? Report a data issue.
In a market where the S&P 500 yields a paltry 1.4%, Pfizer and Bristol Myers Squibb offer income investors a rare combination of outsized yields and deep value. With forward P/E ratios below 11, these beaten-down pharma giants could re-rate as pipeline successes materialize.
Pfizer and Bristol Myers Squibb combine high dividend yields with deep healthcare pipelines, offering a compelling income-entry into a sector facing patent cliffs but also rich in innovation. For healthcare investors, the stocks demand a long-term view on drug development amid evolving policy risks.
Source: The Motley Fool · fool.com